The U.S. Food and Drug Administration issued a Complete Response Letter for Alkermes’ New Drug Application for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and bipolar 1 disorder, and a CRL for Adamis Pharmaceuticals’ NDA for the high-dose naloxone injection product ZIMHI for the treatment of opioid overdose.

Many Covid-19 survivors are likely to be at greater risk of developing mental illness, psychiatrists said, after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.

Shares of Alkermes were up in trading after the Ireland-based company announced the experimental schizophrenia drug ALKS 3831 was overwhelmingly supported by an advisory committee for the U.S. Food and Drug Administration.

Sunovion Pharmaceuticals Inc. announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine.

Acadia Pharmaceuticals Inc.’s add-on treatment pimavanserin for schizophrenia failed to meet the main goal in a late-stage study.

Newron must delay a trial of the Swiss-listed drugmaker’s prospective schizophrenia medicine evenamide after the U.S. FDA raised concerns about CNS events that emerged in rats and dogs.

An estimated 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help – despite a number of available therapies.

A variety of new preventive measures to help Japan’s rapidly aging population avoid illness and injury went on display at a medical exposition in the port town of Yokohama. The ME-BYO (pronounced mee-bee-yoh) Japan 2015 conference also sought to promote healthier lifestyles for the elderly. One innovation on display was a smartphone application called Mind […]